With the total case surpassing 27000, Nepal Government is on the verge to import Remdesivir, a vaccine used by many of the countries to combat the coronavirus. Clinical trials await in Nepal after the landing of the vaccine.
The drug has not proven to be a cent percent proven cure for the virus, however; it has showed a promising effect to the patients in the critical stage. The emergency use authorization allows health care providers to distribute and administer the Remdesivir, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with a severe case of the disease.
Department of Drug Administration (DDA), on Tuesday, has already invited the companies to bid for the Remdesivir for the clinical trial in Nepal.
The FDA (Food and Drug Administration) of USA has given the green signal for the clinical trials to the flagship product of Gilead sciences. Director General Narayan Dhakal, representing Department of Drug Administration stated that “While still on trial we can’t confirm that this drug will cure the virus for sure.
Yet, many countries like India, China and New Zealand that went through the clinical trials have confirmed the positive effect of the drug on severely ill people”. Nepal’s Medical Council (NMC) has already enlisted Remdesivir for primary medication. According to DDA, an unit of Remdesivir can up to NRS 20,000 in Nepal, inclusive of the freight charges. Until now, three companies have proposed the procurement bid and all of them are granted the permission to buy the drug from USA or India.
Limited numbers of supply and distribution channels, with the chemical itself posing high difficulty to synthesize, are the major reasons for the high price tag. Dr Prabhat Adhikari, a virologist, mentioned that import of the drug in high volume can reduce the overall cost because of low average freight and commissions expenses. Experts forecast the expected sales of Remdesivir to surpass $3 billion and continued high demand will further hike the price of the drug.